Prevalence of human papillomavirus in abnormal cervical smears in Malaysian patients

Asian Pacific Journal of Cancer Prevention

Volumn 10, Issue 2, 2009, Pages 303-306

  Sharifah, Noor Akmal ^a   Seeni, A ^a   Nurismah, M I ^a   Clarence Ko, C H ^a   Hatta, A Z ^b   Ho, Ng Paul ^b   Rafaee, T ^b   Adeeb, N ^b   Jamal, A R ^a  

^a UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^b UNIVERSITI KEBANGSAAN MALAYSIA MEDICAL CENTER   (Malaysia)

Author keywords

Cervical smears; HPV genotypes; HR HPV; PCR direct sequencing

Indexed keywords

EID: 67650917753     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bosch FX, de Sanjos S (2003). Chapter 1: Human Papillomavirus and cervical cancer-burden and assessment of causality. J Natl Cancer Inst Monogr, 31, 3-13.
2. Bosch FX, Manos MM, Muñoz N, et al (1995). Prevalence of Human Papillomavirus in cervical smear: a worldwide perspective. J Natl Cancer Inst, 87, 796-802.
3. Castle PE, Solomon D, Schiffman M, et al (2005). Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst, 97, 1066-71.
4. Clifford GM, Smith JS, Aguado T, et al (2003). Comparison of human papillomavirus type distribution in high grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer, 89, 101-5.
5. Clifford GM, Smith JS, Plummer M, et al (2003). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer, 88, 63-73.
6. Cogliano V, Baan R, Straif K, et al (2005). WHO International Agency for Research on Cancer. Carcinogenecity of human papillomavirus. Lancet Oncol, 6, 204.
7. Cox JT (1996). Clinical utility of HPV testing. In: Obstetrics and Gynaecology Clinics of North America (Editor, Lorincz AT) 23(4) pp. 811-852. WB Saunders, Publication.
8. Ferlay J, Bray F, Pisani P, et al (2004). GLOBOCAN 2002: Cancer Incidence, mortality and prevalence. Worldwide IARC Cancer Base no.5. Version 2.0 Lyon: IARC Press.
9. Gaarenstroom KN, Melkert P, Walboomers JM, et al (1994). Human papillomavirus DNA and genotypes; prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer, 4, 73-8.
10. Ho GY, Bierman R, Beardsley L, et al (1998). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med, 338, 423-8.
11. Ho GY, Burk RD, Klein S, et al (1995). Persistent genital HPV infection is a risk factor for persistent cervical dysplasia. J Natl Cancer Inst, 87, 1365-71.
12. Kataja V, Syrjänen S, Mäntyjärvi R, et al (1992). Prognostic factors for cervical human papillomavirus infections. Sex Transm Dis, 19, 54-60.
13. Khan MJ, Castle PE, Lorincz AT, et al (2005). The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst, 97, 1072-9.
14. Lim GCC, Halimah Y, Lim TO (2002). The First Report of the National Cancer Registry: Cancer Incidence in Malaysia 2002 [online]. Available from URL: http://www.crc.gov.my/ncr.
15. Muñoz N, Bosch FX, de Sanjosé S, et al (2003). International Agency for Research on Cancer Multicenter Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med, 348, 518-27.
16. National Cancer Institute. Cervical Cancer Physician data query (PDQ): Screening (health professional version) [online]. Available from URL: http://cancer.gov/.
17. Parkin DM, Pisani P, Ferlay J (1993). Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer, 54, 606.
18. Poljak M, Barlik J, Seme K, et al (1995). Isolation of DNA from archival Papanicolaou-stained cytological smears using a simple salting-out procedure. J Clin Pathol, 48, M55-6.
19. Puranen M, Saarikoski S, Syrjänen K, et al (1996). Polymerase chain reaction amplification of human papillomavirus DNA from archival, Papanicolaou-stained cervical smears. Acta Cytol, 40, 391-5.
20. Remmink AJ, Walboomers JM, Helmerhorst TJ, et al (1995). The presence of persistent high risk human papillomavirus genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer, 61, 306-11.
21. de Roda Husman AM, Snijders PJ, Stel HV, et al (1995). Processing of long-stored archival cervical smears for human papillomavirus detection by polymerase chain reaction. Br J Cancer, 72, 412-7.
22. Schiffman M, Herrero R, Desalle R, et al (2005). The carcinogenicity of human papillomavirus types reflects viral evolution. Virology, 337, 76-84.
23. Shibata D, Fu YS, Gupta JW, et al (1988). Detection of human papillomavirus in normal and dysplastic tissue by polymerase chain reaction. Lab Invest, 59, 555-9.
24. Sirovich BE, Welch HG (2004). The frequency of Pap smear screening in the United States. J Gen Intern Med, 19, 243-50.
25. The National Centre for HIV, STD, and TB Prevention. Genital HPV Infection [online]. Available from URL: http:www.cdc.gov/.
26. Van Den Brule AJ, Walboomers JM, Du Maine M, et al (1991). Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer, 48, 404-8.
27. Walboomers JM, Jacobs MV, Manos MM, et al (1999). Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol, 189, 12-9.
28. Walboomers JM, de Roda Husman AM, Snijders PJ, et al (1995). Human papillomavirus in false negative archival smears: implications for screening for cervical cancer. J Clin Pathol, 48, 1-5.
29. Wheeler CM, Hunt WC, Schiffman M, et al (2006). Human papillomavirus genotypes and the cumulative 2-year risk of cervical precancer. J Infect Dis, 194, 1291-9.
30. Zur Hausen H (1994). Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. In: Human Pathogenic Papillomavirus (Editor, Zur Hausen H) pp 131-56. Springer Verlag, Berlin.